The CEO of UnitedHealth Group said Thursday that shortcomings of America’s health care system must be addressed.
Congress and regulating agencies including the FTC and HHS scrutinized PBM business practices and ... down 32.2% from its 2022 performance due to biosimilar competition. One might expect that ...
“From our inception, we always believed that a transparent approach where we were paid to administer and then had some compensation transparently based on performance was a better approach.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback